Canaccord Genuity Reiterates a 'Buy' on St. Jude Medical (STJ); Recommend Adding to Positions

June 25, 2012 8:29 AM EDT Send to a Friend
Get Alerts STJ Hot Sheet
Price: $45.15 -0.04%

Rating Summary:
    10 Buy, 10 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 18 | New: 13
Trade STJ Now!
Canaccord Genuity reiterates a 'Buy' on St. Jude Medical (NYSE: STJ) price target of $50.00 (from $45.00).

Analyst, Jason R. Mills, said, "Just prior to the market close on Friday, STJ announced it had finished its analysis of the Durata lead externalization that was recorded in FDA’s MAUDE database a few weeks ago and caused serious consternation among investors. After assessing the lead in question, STJ concluded the failure was related to external abrasion resulting from contact with another lead or a calcified heart valve – both of which occur with all companies’ lead systems from time to time."

For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.

Shares of St. Jude Medical closed at $37.90 yesterday, with a 52 week range of $32.13-$49.79.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Canaccord Genuity

Add Your Comment